Related Experiment Videos
Novel dihydropyrazine analogues as NPY antagonists
Sing-Yuen Sit1, Yazhong Huang, Ildiko Antal-Zimanyi
1Department of Neuroscience/Genitourinary Drug Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492-7660, USA. sits@bms.com
Bioorganic & Medicinal Chemistry Letters
|January 30, 2002
Summary
Researchers synthesized dihydropyrazine derivatives to explore neuropeptide-Y(1) (NPY-Y1) receptor antagonists. These new compounds offer novel insights into structure-activity relationships for optimal NPY receptor binding.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Dihydropyridine compounds are lead candidates for neuropeptide-Y(1) (NPY-Y1) receptor antagonist development.
- The NPY-Y1 receptor is a target for potential therapeutic interventions.
Purpose of the Study:
- To synthesize and evaluate dihydropyrazine derivatives as analogs of existing dihydropyridine NPY-Y1 receptor antagonists.
- To expand the structure-activity relationship (SAR) study of NPY-Y1 receptor ligands.
- To investigate how structural modifications impact molecular properties and receptor binding.
Main Methods:
- Synthesis of a novel series of dihydropyrazine derivatives.
- Characterization of the synthesized compounds.
- Evaluation of ligand affinity and selectivity for NPY-Y1 receptors (e.g., using IC50 values in SK-N-MC cells).
Main Results:
- Successful synthesis of dihydropyrazine analogs preserving the core molecular structure.
- The new derivatives exhibit altered molecular polarization and electron distribution compared to parent dihydropyridines.
- The compounds demonstrate potential as NPY-Y1 receptor ligands, providing valuable SAR data.
Conclusions:
- Dihydropyrazine derivatives represent a promising avenue for NPY-Y1 receptor antagonist research.
- Structural modifications can significantly alter ligand properties, offering new insights into receptor interactions.
- This study provides crucial SAR information for optimizing NPY receptor antagonist design.